Introduction {#Sec1}
============

Tuberculosis (TB) caused by *Mycobacterium tuberculosis* (*Mtb*) is, worldwide, the leading cause of human fatalities due to any infectious disease (WHO, [@CR32]). Of great concern is the emergence of multi-drug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB, which has further exacerbated the global burden of TB and at the same time continues to lead to a reduction in clinical recovery rates (WHO, [@CR32]).

Ethambutol (EMB) is one of the five front-line drugs used to treat TB and is particularly important in MDR-chemotherapy regime (Alliance, [@CR3]). It exhibits its mode of action by inhibiting the biosynthesis of arabinogalactan (AG) (Takayama and Kilburn, [@CR30]; Mikusova et al., [@CR19]; Lee et al., [@CR14]), a key component of the *Mtb* cell wall mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (Jankute et al., [@CR10]). However, the molecular basis for this inhibition has remained unresolved (Mikusova et al., [@CR19]). Resistance to ethambutol has been shown to be caused by mutations within the *embCAB* operon (*embC*, *embA*, and *embB*) that encode membrane-associated arabinosyltransferases, amongst which EmbB has been identified as the primary target (Safi et al., [@CR24]; Sun et al., [@CR29]). Functional studies have shown that all the Emb proteins play key roles in cell wall synthesis. Specifically, EmbA and EmbB participate in arabinosylation of AG, which is linked via covalent attachment to the outer mycolic acids layer and the inner peptidoglycan layer, ultimately forming the cell wall core (Escuyer et al., [@CR8]), thus acting as a natural barrier surrounding the cell membrane (Fig. [1](#Fig1){ref-type="fig"}A). On the other hand, EmbC is involved in the formation of lipoarabinomannan (LAM), a glycolipid which may modulate the host immune response during *Mtb* infection (Goude et al., [@CR9]).Figure 1**Arabinosyltransferase activity of EmbB and inhibition by ethambutol**. (A) Schematic representation of the components and assembly of the mycobacterial membrane and cell wall. EmbB catalyzes the addition of an arabinose residue in an α(1→3) linkage from DPA resulting in the precursor for a subsequent extension by AftB, further resulting in the characteristic terminal branching hexamotif found in AG. (B) Arabinosyltransferase activity measured using di-arabinoside NV6. The \[^14^C\] labeled arabinose transferred from DP\[^14^C\]A to the product was confirmed by autoradiographic thin layer chromatography (TLC). See also Figures S1 and S9

The *embB* gene has been shown to be essential for the survival of *Mtb* in culture (Sassetti et al., [@CR25]), whereas a *Mycobacterium smegmatis* (*Msm*) *embB*-knockout strain was shown to be viable but possessed profound morphological alterations upon gene inactivation (Escuyer et al., [@CR8]). Furthermore, EmbB has been shown to play a key role in forming the characteristic terminal hexarabinofuranosyl motif (Fig. [1](#Fig1){ref-type="fig"}A) of AG, which is the template for mycolylation (Escuyer et al., [@CR8]; Jankute et al., [@CR10]). Together with the other Emb proteins (EmbA and EmbC), EmbB belongs to the glycosyltransferase C (GT-C) superfamily (Berg et al., [@CR4]; Lairson et al., [@CR11]), whose structures comprises an N-terminal transmembrane domain and a C-terminal soluble domain located on the periplasmic side of the membrane (Berg et al., [@CR4]). However, the Emb proteins show no overall sequence similarity to any other GT-C members or any other proteins beyond mycobacteria or related genera (Berg et al., [@CR5]). The lipid donor utilized by EmbB is decaprenyl-phosphate-arabinose (DPA), which is the only proven arabinose donor for mycobacterial species (Lee et al., [@CR13]). In a very recent study three dimensional structures of *Mtb* and *Msm* EmbA-EmbB heterodimer complexes and *Msm* EmbC~2~ homodimer complex were determined (Zhang et al., [@CR35]). Nevertheless, *embA* knockout *Msm* (斜体) strain can survive, indicating EmbB protein can work alone in cell (Escuyer et al., [@CR8]). However, other fashions of the Emb-containing assembly, *i.e.* (斜体), EmbB as an individual protein has not been reported.

Here, we have characterized EmbB in terms of its structure, catalytic mechanism and its inhibition by ethambutol. We present the cryo-EM structures of a full-length *Msm* EmbB in two distinct conformations, which we refer to as the "resting" and donor-bound "active" states at 3.6 Å and 3.5 Å resolution, respectively. EmbB is observed as a dimer along with an acyl-carrier-protein (AcpM) associated with each protomer, thus forming a heterotetrameric EmbB~2~-AcpM~2~ complex. We show that ethambutol inhibits the enzymatic activity of the EmbB~2~-AcpM~2~ complex and structurally identify the site that is most susceptible to ethambutol resistance based on isolates from clinical studies.

Results and discussion {#Sec2}
======================

Enzyme purification, characterization and structure determination {#Sec3}
-----------------------------------------------------------------

To gain insights into the structure and function of EmbB, we screened several mycobacterial orthologues to assess protein yield and purity. From these studies, we identified *Msm* EmbB (MSMEG_6389) as the ideal candidate for investigation. *Msm* EmbB, whose sequence is 69.6% identical to *Mtb* EmbB (Rv_3795) was cloned into the pMV261 vector containing a 10× His tag fusion at its C-terminus. *Msm* was then used as its host for overexpression (Snapper et al., [@CR28]). Detergent purified followed by amphipol exchanged EmbB protein (Fig. S1A--C) was then subjected to cryo-EM analysis.

The natural acceptor of EmbB remains to be defined, but cell-free arabinosyltransferase activity could be measured using a diarabinoside, NV6, as an acceptor analog (Fig. [1](#Fig1){ref-type="fig"}B). An EmbB arabinosyltransferase assay was used to determine the transfer of \[^14^C\]-arabinose from DP\[^14^C\]A to NV6. The resulting product, NV12, was identified by autoradiographic thin-layer chromatography (TLC) (Fig. [1](#Fig1){ref-type="fig"}B). NV12 had a similar retardation factor to a synthetic tri-arabinoside suggesting the transfer of a single \[^14^C\]-arabinose unit from DP\[^14^C\]A, a feature common to these acceptor analogs (Lee et al., [@CR13]). Not surprisingly, EmbB arabinosyltransferase activity is inhibited by ethambutol (Fig. [1](#Fig1){ref-type="fig"}B). Given NV6 allows three potential glycosylation sites at 2-OH, 3-OH and 5-OH on the terminal non-reducing arabinose, we sought to use a chemical biology approach to further characterize the \[^14^C\]-arabinose containing NV12 product. The related NV13 acceptor, where the 3-OH position of the terminal arabinose unit of NV6 is blocked by an azide group was used in subsequent cell-free experiments for purified EmbB, EmbC, and the abundant AftB activity from *Msm* membranes (Lee et al., [@CR13]), to determine the resulting new glycosidic linkage in NV12 catalyzed by EmbB, which is presumably an α(1→3)-linkage based on previous studies (Escuyer et al., [@CR8]). The azide group in NV13 prevented glycosylation by EmbB but allowed purified EmbC to catalyze an ethambutol-sensitive α(1→5)-linkage (NV15), and an ethambutol-resistant AftB β(1→2)-linkage (NV14) (Fig. S1E). In addition, 2D heteronuclear single quantum correlation (HSQC) NMR experiments using purified AG from wild type *Msm* and the *Msm embB* knockout strain were consistent with the above cell-free arabinosyltransferase data and showed that the cell wall from the knockout strain lacked the terminal linkage of arabinose unit by virtue of the absence of the characteristic 2-α-Ara*f*-3 NMR signal (Fig. S1F).

Purified, amphipol exchanged EmbB appeared as homogeneous and dispersed particles in negative staining EM and when embedded in vitreous ice (Fig. S2A). 2D class averages revealed a dimeric assembly of EmbB (Fig. S2B) with two attachments on the cytoplasmic side, subsequently identified by silver staining (Fig. S1C) and mass-spectrometry (Fig. S1D) as the endogenous acyl-carrier-protein AcpM (*MSMEG*\_4326). Two major classes generated by 3D classification were selected and subjected to individual refinements, ultimately yielding two different reconstructions at 3.5 Å and 3.6 Å overall resolution (Fig. S2C-F). The quality of both maps allowed us to build, *de novo*, two near-atomic models of EmbB that include most of the residues (Tables S1 and S2), while AcpM could be docked and refined using a homologous structure (PDB: 1KLP (Wong et al., [@CR34])). Additional features in the cryo-EM map could be accounted for by the donor substrate, DPA, whose presence was confirmed by mass spectrometry (Fig. S1G). This feature shows DPA is bound in its expected binding cavity in the asymmetric EmbB dimer, and the potential by-product, decaprenyl phosphate (DP) bound to regions that are likely in the transmembrane domain of EmbB.

Two distinct states of EmbB~2~-AcpM~2~ complex {#Sec4}
----------------------------------------------

The EmbB~2~-AcpM~2~ complex is captured in two states, one with C2-symmetry and the other that is asymmetric (Fig. [2](#Fig2){ref-type="fig"}A). In both reconstructions, each EmbB protomer is associated with an AcpM on its cytoplasmic side (Fig. [2](#Fig2){ref-type="fig"}A), resulting in a heterotetrameric assembly. Given their differences in composition and conformation, the two states are referred to as the asymmetric "donor-bound" active state and the symmetric "resting" state (Fig. [2](#Fig2){ref-type="fig"}A). The asymmetry refers not only to the asymmetric binding of DPA, but also to the asymmetry of the enzyme dimer assembly (see below). The EmbB protomers in the two states share common structural features which include two periplasmic domains (PDs) and 15 transmembrane helices (TMH) arranged into an approximately crescent-shaped bundle (Fig. [2](#Fig2){ref-type="fig"}B--E). The PDs comprise a PD~N~ located between TMH1 and TMH2 and a PD~C~ at the C-terminus (Fig. [2](#Fig2){ref-type="fig"}B and [2](#Fig2){ref-type="fig"}C). PD~C~ features a jelly-roll-fold subdomain coordinated with a Ca^2+^ ion, similar to the previously reported crystal structure of the C-terminal soluble domain of EmbC from *Mtb* (Alderwick et al., [@CR2]), and a mixed α/β fold subdomain, whose interactions with both the TM domain and PD~N~ are observed here in the intact EmbB structure (Figs. [2](#Fig2){ref-type="fig"}C, S3B and S3C). PD~N~ also adopts a jelly-roll-fold and interacts with the C-terminal tail of PD~C~ by forming a three-stranded β-sheet (Figs. [2](#Fig2){ref-type="fig"}B, 2C and S3C), which may help to stabilize the entire PD. Not surprisingly, this overall folding represented by EmbB~2~-AcpM~2~ complex agrees well with that of the previously reported Emb proteins (Zhang et al., [@CR35]).Figure 2**Architecture and asymmetry in the EmbB**~**2**~**-AcpM**~**2**~**complex**. (A) Top row: Cartoon representation of the "resting" state (left) and "donor-bound" active state (right). DPA is drawn as red spheres. Bottom row: Cryo-EM maps of the two states, DPA is buried inside and is not shown in the map (bottom right). (B) Structure of an EmbB protomer viewed from the dimer interface, with a spectral coloring from purple (N terminus) to red (C terminus), the mixed α/β subdomain of PD~C~ has colored red and jellyroll fold subdomain in light brown. (C) Topology diagram for an EmbB protomer using the same color scheme as (B). (D) Superposition of the "resting" and "donor-bound" states. Left and right images have alternate views and (E) is from the top showing the transmembrane helices, and a translation of \~16 Å along with the dimer interface and in the plane of the membrane. (F) Superposition of the membrane portions of EmbB for the two unbound promoters shows the conformation change upon activation. (G) View from the periplasm, showing the movement of the periplasmic domain in black (resting state), grey (expected clash position) and yellow (active state). See also Figs. S2, S3 and S4 and Table S1, S2

The two EmbB~2~-AcpM~2~ complexes show significant differences in their subunit organizations (Fig. [2](#Fig2){ref-type="fig"}A, and [2](#Fig2){ref-type="fig"}D--G). Most significantly, the two EmbB protomers in the DPA bound complex are asymmetrically associated. Relative to the DPA-bound protomer, the other EmbB protomer is translated by \~16 Å along the dimer interface, and in the plane of the membrane (Fig. [2](#Fig2){ref-type="fig"}D and Movie S1). This change in subunit organization dramatically alters the dimer interface, in which, for instance, the distance between the pair of TMH11 at the interface has halved, resulting in a more compact active site (Fig. [2](#Fig2){ref-type="fig"}E). While this asymmetric movement is induced, the expected steric clashes in the periplasmic domains of the two EmbB protomers are resolved by rearrangements of the PLs and PDs within the unbound protomer (Fig. [2](#Fig2){ref-type="fig"}F, 2G, and Movie S1).

DPA binding in the active complex {#Sec5}
---------------------------------

In the "active" complex, a semi-confined gulf is formed in the membrane space that is surrounded by TMH1, TMH7-9 and TMH11 from the DPA-bound EmbB protomer and TMH10, TMH13, and TMH14 from the other protomer (Figs. [2](#Fig2){ref-type="fig"}E, [3](#Fig3){ref-type="fig"}A and 3B). Once the nearby side-chains were assigned (Fig. S4), the cryo-EM map shows a long tadpole-shaped signal in the hydrophobic groove formed by TMH7-9, heading to the presumed active site which is expected to be in the periplasmic space (Fig. [3](#Fig3){ref-type="fig"}B and [3](#Fig3){ref-type="fig"}C). Given that endogenous DPA was identified during purification (Fig. S1G), it was reasonable to build a DPA into this region (Fig. [3](#Fig3){ref-type="fig"}A and [3](#Fig3){ref-type="fig"}B). The whole of the DPA fits into this part of the map with the arabinose moiety and phosphate group fitting into a charged cavity just above the membrane surface (Fig. [3](#Fig3){ref-type="fig"}C and [3](#Fig3){ref-type="fig"}D). This cavity is bordered by PL2 which contains the catalytically relevant D(285)D(286)x motif (Berg et al., [@CR5]); PL5 which is organized as two short α-helices (α5 and α6) and a following loop region; and the mixed α/β subdomain of PD~C~ (Fig. [3](#Fig3){ref-type="fig"}C). As a result of DPA binding, several residues around DPA are repositioned (Fig. [3](#Fig3){ref-type="fig"}D). For instance, the phosphate group is coordinated in place by R495~PL5~, while the arabinose moiety forms hydrogen bonds with E313~PL2~ and Q431~PL4~ which themselves are further stabilized by N304~PL2~ and Y320~PL2~ (Fig. [3](#Fig3){ref-type="fig"}D). W505~α6~ and T518 on PL5 also hold the DPA headgroup from the other side of the cavity (Fig. [3](#Fig3){ref-type="fig"}D). Most of the residues in this cavity are highly conserved amongst mycobacterial EmbB proteins (Fig. S8), and mutations within this hydrophilic cavity result in severe loss of the arabinosyltransferase activity (Figs. S5A and 5B). The last seven prenyl groups of DPA extend to the other half of the hydrophobic groove via extensive hydrophobic interactions with I421~TMH7~, V438~TMH8~, I448~TMH8~, I468~TMH9~ and I469~TMH9~ in the membrane space, with the end of the tail interacting with F670~TM14~ from the other EmbB protomer (Fig. [3](#Fig3){ref-type="fig"}E). Collectively, the PLs, PD~C~, TMH7, bended TMH8, TMH9 of the DPA-bound EmbB protomer and the TMH14 from the other protomer shape an ideal environment to accommodate DPA in the active state of the complex. Another structural rearrangement upon DPA binding, by comparing the structures of the two states, involves α6 in PL5, a short α helix that interacts with DPA, whereas in the resting state, this region is disordered (Fig. [3](#Fig3){ref-type="fig"}F). Considering that the bound DPA is the major composition difference between the two states, it is reasonable to speculate that the dramatic structural rearrangement of the enzyme complex in the active state occurs upon DPA binding, and is mediated by the induced disorder-to-helix transition of α6 at the dimer interface. This kind of concerted disordered-to-helix transition of a functional periplasmic loop along with donor binding has been proposed to enable access to the acceptor in other glycosyltransferases such as ArnT from *Cupriavidus metallidurans* in complex with its lipid substrate undecaprenyl phosphate (UndP) and PglB from *Campylobacter lari* with lipid-linked oligosaccharide (LLO) (Lizak et al., [@CR17]; Vasileios I. Petrou et al., [@CR31]; Napiorkowska et al., [@CR20]).Figure 3**DPA binding cavity in EmbB**. (A) Left: Cartoon representation of the EmbB~2~-AcpM~2~ complex in the "donor-bound" active state. Right: Cavity formed in the membrane space surrounded by TMH1, TMH7-9, and TMH11 from the DPA-bound EmbB protomer and the TMH10, TMH13, and TMH14 from the other protomer. DPA is in pink. (B) The complete DPA in the groove, with surrounding TMHs from both protomers. Cryo-EM map is shown in colored mesh. (C) The DPA-bound cavity viewed just above the membrane surface is bordered by PL2 which contains the catalytically relevant D(285)D(286)X motif, PL5 which is organized as two short α-helices (α5 and α6), and the mixed α/β subdomain of PD~C~. DPA is shown in pink. (D) Zoom-in view of the catalytic cavity, showing side-chains of residues interacting with the DPA head-group and a putative metal ion. Interactions are indicated by dashed lines. (E) The hydrophobic decaprenyl tail of DPA in the groove of the dimer interface, making several hydrophobic interactions, and a C-H···π-interaction with F670 from the empty protomer. (F) DPA binding cavity viewed from the periplasm. EmbB protomers from the "resting" state (purple) and "donor-bound" active state (blue) are superimposed. The dotted line from Q502 to G521 indicates a disordered loop in the "resting" state, which is stabilized in the active state through interactions with DPA. See also Figs. S1G, S5 and S8

EmbB-AcpM interaction {#Sec6}
---------------------

AcpM has a four-helix topology arranged in a right-handed bundle held together by interhelical hydrophobic interactions (Wong et al., [@CR34]) (Fig. [2](#Fig2){ref-type="fig"}C). The two AcpM molecules bind to each of the two EmbB protomers through extensive electrostatic interactions on the cytoplasmic surface of EmbB (Fig. [4](#Fig4){ref-type="fig"}A). Helix-2 and helix-3 of AcpM are intimately engaged with the cytoplasmic loop 1 (CL1) of EmbB, which is a long positively charged linker between TMH2 and TMH3 (Fig. [4](#Fig4){ref-type="fig"}A). This is consistent with the known role of helix-2 in AcpM as a contact site with its target proteins, such as AcpS (Parris et al., [@CR21]) (Fig. S6). The AcpM attached to the DPA-bound EmbB protomer has the better-resolved structure in our cryo-EM reconstructions (Figs. S2C, S2F, and S4B). Most of its side-chains have been assigned (Table S2). Three pairs of interactions are revealed: D53 and D61 of AcpM form salt-bridges with R454~TMH8b~ and R249~CL1~ of EmbB, and S41~AcpM~ forms a hydrogen bond with R253~CL1~ of EmbB (Fig. [4](#Fig4){ref-type="fig"}A). R249~CL1~, R253~CL1~, and R454~TMH8b~ in EmbB are highly conserved across mycobacterial species (Fig. S8). When a triple-alanine mutant (R249, R253, and R454) of EmbB that abolished its interaction with AcpM (Fig. S1C) was transformed into *Msm embB* knockout strain, a moderate loss (at \~40%) of the 3-arm branching signal of AG was observed (Fig. S1G), suggesting that AcpM is most likely functionally associated to arabinosyltransferase activity *in vivo*, regardless the equivalent mutation had little effect on the cell-free arabinosyltransferase activity (Fig. S5A).Figure 4**EmbB-AcpM interaction and implications of by-product recycling**. Interface of EmbB-AcpM interaction, AcpM has a four-helix topology. Three pairs of residues participate in the EmbB-AcpM interaction, side-chains are shown as sticks

Active site and possible acceptor pathway {#Sec7}
-----------------------------------------

Glycosyltransferases are classified as either "inverting" or "retaining" based on two stereochemical outcomes in the formation of the new glycosidic bond at the anomeric carbon (Lairson et al., [@CR11]). Emb proteins are believed to be inverting enzymes based on the fact that nearly all of the arabinose residues in the DPA-involved extension of AG are in an α-configuration (Jankute et al., [@CR10]) (except for the non-reducing end of AG catalyzed by AftB (Seidel et al., [@CR26])), while DPA is in a β-configuration (Lee et al., [@CR15]). For a conventional inverting glycosyltransferase reaction, upon both substrates (the donor and acceptor) reaching the catalytic site, a key catalytic step relies on an active site side-chain, which serves as a base catalyst that deprotonates the nucleophile of the acceptor, enabling the following nucleophilic attack at the anomeric carbon (Breton et al., [@CR6]). In our structure, the arabinose moiety of DPA is positioned between two acidic residues D285 and E313 in the catalytic pocket (Fig. [3](#Fig3){ref-type="fig"}D). D285 belongs to the highly conserved DDx GT-C motif and is the predicted catalytically essential residue (Berg et al., [@CR5]). Mutation of this residue in EmbB in this study and the equivalent residue D279 in EmbC as previously reported (Berg et al., [@CR5]) led to a complete loss of activity (Fig. S5B). In EmbB, D285 locates at the junction of two cavities, one of which harbors the arabinose moiety and phosphate group of DPA, and the other, opposite to the DPA cavity, provides polar access to the dimer interface above the membrane boundary (Figs. [5](#Fig5){ref-type="fig"}A, [5](#Fig5){ref-type="fig"}B, and 5D). Altogether, this suggests that D285 is likely the key active site residue involved in catalysis. In our structure, DPA aligns its C5 atom close to D285, whereas the C1 atom is approximately 8 Å from the side-chain of D285. It is speculated that a further conformational change is required, possibly upon acceptor binding, allowing the DPA to move deeper into the cavity and reorient its C1 atom for α(1→3) glycosidic bond formation. This shift could involve a repositioning of the phosphate group much deeper into the DPA cavity and closer to D285.Figure 5**Active site and possible acceptor pathway**. (A) DPA bound cavity viewed from PD~C~. An open path (W-pathway) between W1012 and W505 connecting to the DPA arabinose moiety at the dimer interface is indicated by the dashed curves. Surrounding side-chains interacting with DPA are shown as stick models. (B) Orthogonal view of (A) with the W-pathway to the DPA arabinose moiety is indicated by a dashed circle. (C) Orthogonal and zoom-in view of (B). (D) Flexibility of PLs in the empty protomer suggests an extending of the presumed acceptor approaching pathway in panel (A) which is indicated by W504 at the entrance. See also Fig. S3E

EmbB catalyzes the penultimate step of AG synthesis. We have previously reported that EmbB functions in a coordinating way with EmbA (Zhang et al., [@CR35]), nevertheless, our cell-free assay has confirmed that purified EmbB alone is functional using NV6 as acceptor. Thus, it can be inferred that EmbB may play dual roles in cells, by either forming a homodimer or a heterodimer with EmbA, depending on the physiological concentration of these proteins. Therefore, the native acceptor of EmbB could be a relatively mature arabinan chain before the terminal 3-arm branch of the characteristic hexa-arabinan motif (Fig. [1](#Fig1){ref-type="fig"}A). The possible acceptor entry pathway could be deduced based on the location of the identified donor binding cavity and the putative active site. This polar pathway as mentioned above is a tryptophan-rich region that we refer to as the "W-pathway" (Fig. [5](#Fig5){ref-type="fig"}A). This W-pathway is formed by a series of tryptophan residues W308, W504, W505, W972, and W1012. The first three tryptophan residues, located on the DDX-motif-containing PL2 and conformational change modulator PL5, extend to the arabinose moiety of DPA, while the latter two tryptophan residues are located on the mixed α/β fold subdomain of PD~C~. The role of W972 was previously reported to be critical in terms of both of the binding affinity with acceptor and the enzymatic activity in EmbC (W985 in EmbC corresponds to W972 in EmbB) (Alderwick et al., [@CR2]). These tryptophan residues are only partially conserved amongst EmbA, EmbB, and EmbC. The differences might reflect the fact that Emb proteins are different enzymes with different substrate specificities. Furthermore, previous studies have attributed the C-terminal domain of the Emb proteins to a critical role in acceptor substrate recognition and arabinan chain extension (Shi et al., [@CR27]; Alderwick et al., [@CR2]). Consistent with this, in the active state structure, several regions of the PD~C~ are missing in the DPA unbound EmbB protomer (Figs. [5](#Fig5){ref-type="fig"}D and S3E). The flexibility of these missing regions could be the result of the absence of the acceptor when the EmbB~2~-AcpM~2~ complex is activated by the donor. Consequently, this region in PDc may outline a fairly broad and open pathway leading straight into the W-pathway headed by W504 which locates in the dimer interface (Fig. [5](#Fig5){ref-type="fig"}D), thus indicating a macroscopic acceptor entry pathway.

Proposed catalytic cycle for the arabinosyltransferase complex {#Sec8}
--------------------------------------------------------------

In this study, we have determined the structures of a substrate unbound EmbB~2~-AcpM~2~ complex in a presumed resting state and a donor DPA-bound pre-catalytic conformation which we define as the "active" state. The two structures of EmbB~2~-AcpM~2~ suggest that the binding of substrates is a sequentially coupled process with substantial conformational changes upon the binding of the two substrates.

We hypothesize that DPA binding activates the EmbB dimer by triggering conformational changes. Once the EmbB~2~-AcpM~2~ complex is activated, the glycosyltransferase reaction can occur in the following defined steps (Fig. [6](#Fig6){ref-type="fig"}).Figure 6**A proposed catalytic cycle for the arabinosyltransferase complex EmbB**~**2**~**-AcpM**~**2**~. The components of the complex are colored as in Fig. [1](#Fig1){ref-type="fig"}B. The arabinofuranosyl motif of the donor (tetraarabinan) and product (pentaarabinan) are depicted as a chain of cyan pentagons (the arabinose moiety transferred from DPA is in red). Donor (DPA) and by-product (DP) molecules shown as spheres in their different locations are colored as Fig. [4](#Fig4){ref-type="fig"}A and [4](#Fig4){ref-type="fig"}B. The bold arrow lines in grey, red and blue indicate the resting state, activation and processing states during turn-over. Dashed arrow lines indicate a possible recycle mechanism of DP through a switching of DP-carrying AcpM and a hollow one. Different states in the active phase are labeled as A-I, A-II, A-III, A-IV

A-I. The acceptor is recognized and threaded by PD~C~ and enters the active site through the W-pathway, forming an enzyme-donor-acceptor ternary complex (A-II) ready for the reaction. The DPA bound EmbB~2~-AcpM~2~ structure in this study represents an intermediate state before C1 of DPA reaches the optimal position for catalysis. Hence, to form the ternary complex a series of precisely arranged conformational changes are required to allow both substrates to be oriented optimally.

A-II. Based on the catalytically essential role of D285 and canonical mechanism of an inverting glycosyltransferase (Qasba et al., [@CR22]; Lairson et al., [@CR11]), the following is rationally proposed: D285 deprotonates the hydroxyl group on the C3 carbon of the acceptor and activates this hydroxyl group for a nucleophilic attack on the C1 carbon of DPA. A new glycosidic bond is formed (A-III) allowing the newly formed arabinan product and DP (the leaving group) to release from the active site.

A-III. Overall, functional studies confirm that EmbB catalyzes arabinose chain α(1→3) branching with the subsequent product utilized by AftB for the terminal β(1→2) linkage at the non-reducing end of AG. Therefore, it is plausible that product release (A-IV) could be coupled instantaneously with a new round of DPA binding (A-I).

Structural mapping of ethambutol resistance associated mutations and its potential binding site {#Sec9}
-----------------------------------------------------------------------------------------------

In this study, we have shown that anti-TB drug ethambutol inhibits the α(1→3) arabinosyltransferase activity of purified EmbB protein. This agrees with the fact that branching of the terminal hexaarabinan motif in AG can be inhibited by ethambutol (Lee et al., [@CR14]). Numerous mutations in *embB* are causally associated with resistance to ethambutol, but their effects on EmbB structure and function remain unclear. The three-dimensional structure of EmbB provides an unprecedented opportunity to understand the role that the *embB* mutations play in the development of ethambutol resistance in *M*. *tuberculosis*. We selected the top 30 most frequent ethambutol-resistant mutations of EmbB in 1,814 strains from 61 studies in a manually collated drug-resistance database MycoResistance (Dai et al., [@CR7]) (Figs. [7](#Fig7){ref-type="fig"}A and S8). Upon mapping these onto the DPA-bound EmbB structure, we find that most of the mutations concentrate in a radial region centered on the DPA-bound pocket (Fig. [7](#Fig7){ref-type="fig"}A). M306 (equivalent to *Msm* M292) in *Mtb* EmbB which is the most common clinical mutation associated with ethambutol resistance (Ramaswamy et al., [@CR23]; Lee et al., [@CR14]; Safi et al., [@CR24]) is, as expected, also the most predominant (1243/2353) in our analysis (Fig. [7](#Fig7){ref-type="fig"}A). Clinical isolate mutations include M306L, M306V, M306I and M306T substitutions in *Mtb* (Lee et al., [@CR12]; Sun et al., [@CR29]). In *Msm*, M292T mutation results in a 60-fold increase in MIC (Lety et al., [@CR16]). In our cell-free enzymatic activity assay, mutein M292L demonstrates clear resistance to ethambutol (Fig. S5A). Meanwhile, the binding affinity of ethambutol to this mutein also significantly decreases (Fig. [7](#Fig7){ref-type="fig"}B).Figure 7**Mapping of ethambutol-resistant mutation sites**. (A) Log-Scaled histogram of the occurrence of the top 30 frequent ethambutol-resistant mutations in EmbB in 61 studies collected from the drug-resistance database, MycoResistance, and their positions on the DPA-bound EmbB structure, most notably around DPA binding cavity. Mutations with more than 20 occurrences are colored in yellow, and those with more than 1,000 occurrences are in red. (B) MST assays for the binding of ethambutol to wild-type EmbB treated with 2× MIC of BTZ-043 or inhibitor-free during culture and ethambutol resistant mutation hotspot M292L represented by red sphere in (A). Error bars represent mean ± SEM based on three independent measurements. Binding curves and *K*~D~ values are also shown. See also Figs. S7 and S8

The recently reported structure of the ethambutol bound EmbA-EmbB complex enables us to analyze the structural features of the potential drug binding pockets of EmbB2 in this study. When superimposing the EmbB protomer from the EmbB2 in its resting state onto the EmbB subunit of ethambutol-bound EmbA-EmbB complex (Zhang et al., [@CR35]), residues including the catalytic site D285 on EmbB2 were obsereved in the similar position (Figure S7A). Thus it is possible the ethambutol inhibition mode on EmbB2 similar to that on EmbA-EmbB complex by inhibiting substrate binding. Notable shifting (2.9\~4.0 A°) were observed on E313 on PL2 and H580 on PL6 (Figure S7A), likely due to ethambutol binding. The binding affinity of EmbB with ethambutol is greatly enhanced (*K*~D~ = 1.58 μmol/L) (Fig. [7](#Fig7){ref-type="fig"}B) when a DPA synthesis inhibitor, BTZ043 (Makarov et al., [@CR18]), was added during cell culture to obtain overexpressed EmbB protein in a relatively low-abundance DPA environment, which could support this speculation. The competitive inhibition hypothesis of ethambutol is also in agreement with a previous DPA recognition study which demonstrated a rapid accumulation of DPA in ethambutol treated Msm cells(Wolucka et al., [@CR33]).

These analyses will facilitate further experimental studies aimed at understanding how mutations in EmbB and other Emb proteins lead to ethambutol resistance. To be noted, not all ethambutol-resistant strains have *embB* mutations (Alcaide et al., [@CR1]), suggesting that further studies on other resistance associated proteins or pathways are necessary to complete a comprehensive understanding of the mechanisms of ethambutol resistance.

Conclusions {#Sec10}
===========

In this study, cryo-EM single-particle analysis revealed conformational heterogeneity in arabinosyltransferase complex EmbB~2~-AcpM~2~ which we ascribe to evidence for a "resting" and "donor-bound active" state. An acceptor recognition and entry pathway is proposed. We have also characterized EmbB as an α(1→3) arabinosyltransferase and confirmed it is a target of ethambutol. Thus, our work not only unravels the molecular mechanisms involved in substrate recognition for this arabinosyltransferase but also provides a much-anticipated foundation for developing improved anti-TB drugs such as inert DPA analogues.
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